Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Wang, Zhihui ^a,b   Trope, Claes G ^a   Flørenes, Vivi A ^a   Suo, Zhenhe ^a   Nesland, Jahn M ^a   Holm, Ruth ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CDC25B PHOSPHATASE; CDC25C PHOSPHATASE; PHOSPHO CDC25C PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; CDC25A PROTEIN, HUMAN; CDC25B PROTEIN, HUMAN; CDC25C PROTEIN, HUMAN; SERINE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER INFILTRATION; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENE LOCATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; VULVA CARCINOMA; WESTERN BLOTTING; ANTIBODY SPECIFICITY; CELL DIFFERENTIATION; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TUMOR CELL LINE; UPREGULATION; VULVA TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CDC25 PHOSPHATASES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CHI-SQUARE DISTRIBUTION; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PHENOTYPE; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SERINE; TIME FACTORS; UP-REGULATION; VULVAR NEOPLASMS;

EID: 77952484477     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-233     Document Type: Article

References (38)

1. Coulter J, Gleeson N. Local and regional recurrence of vulval cancer: management dilemmas. Best Pract Res Clin Obstet Gynaecol 2003, 17:663-681. 10.1016/S1521-6934(03)00050-6, 12965138.
2. Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 1997, 90:448-452. 10.1016/S0029-7844(97)00298-6, 9277660.
3. Messing MJ, Gallup DG. Carcinoma of the vulva in young women. Obstet Gynecol 1995, 86:51-54. 10.1016/0029-7844(95)00101-V, 7784022.
4. Tyring SK. Vulvar squamous cell carcinoma: guidelines for early diagnosis and treatment. Am J Obstet Gynecol 2003, 189:S17-S23. 10.1067/S0002-9378(03)00792-0, 14532899.
5. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets?. Nat Rev Cancer 2007, 7:495-507. 10.1038/nrc2169, 17568790.
6. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004, 11:1043-1051. 10.1016/j.chembiol.2004.07.007, 15324805.
7. Aressy B, Ducommun B. Cell cycle control by the CDC25 phosphatases. Anticancer Agents Med Chem 2008, 8:818-824.
8. Sasaki H, Yukiue H, Kobayashi Y, Tanahashi M, Moriyama S, Nakashima Y, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer. Cancer Lett 2001, 173:187-192. 10.1016/S0304-3835(01)00669-3, 11597794.
9. Takemasa I, Yamamoto H, Sekimoto M, Ohue M, Noura S, Miyake Y, Matsumoto T, Aihara T, Tomita N, Tamaki Y, Sakita I, Kikkawa N, Matsuura N, Shiozaki H, Monden M. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res 2000, 60:3043-3050.
10. Tsuda H, Hashiguchi Y, Inoue T, Yamamoto K. Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. Oncology 2003, 65:159-166. 10.1159/000072342, 12931023.
11. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, Beach D. CDC25 phosphatases as potential human oncogenes. Science 1995, 269:1575-1577. 10.1126/science.7667636, 7667636.
12. Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G, Ranashinge M, Cady B, Pagano M, Loda M. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest 2000, 106:753-761. 10.1172/JCI9174, 381390, 10995786.
13. Broggini M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, Lissoni AA, Mangioni C, D'Incalci M. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res 2000, 20:4835-4840.
14. Nishioka K, Doki Y, Shiozaki H, Yamamoto H, Tamura S, Yasuda T, Fujiwara Y, Yano M, Miyata H, Kishi K, Nakagawa H, Shamma A, Monden M. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br J Cancer 2001, 85:412-421. 10.1054/bjoc.2001.1934, 2364065, 11487274.
15. Ozen M, Ittmann M. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin Cancer Res 2005, 11:4701-4706. 10.1158/1078-0432.CCR-04-2551, 16000564.
16. Shepherd JH. Cervical and vulva cancer: changes in FIGO definitions of staging. Br J Obstet Gynaecol 1996, 103:405-406.
17. WHO Pathology and Genetics: Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumors 2003, 316-321. Lyon: IARC Press, WHO.
18. Knopp S, Nesland JM, Trope C, Holm R. p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma. Am J Clin Pathol 2006, 126:266-276. 10.1309/E9E8Y9WG5QE3LK29, 16891203.
19. Wang Z, Trope CG, Suo Z, Troen G, Yang G, Nesland JM, Holm R. The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas. BMC Cancer 2008, 8:308. 10.1186/1471-2407-8-308, 2577690, 18950492.
20. Jorgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A, Florenes VA. Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. Biochem Biophys Res Commun 2005, 329:266-274. 10.1016/j.bbrc.2005.01.143, 15721302.
21. Xu X, Yamamoto H, Sakon M, Yasui M, Ngan CY, Fukunaga H, Morita T, Ogawa M, Nagano H, Nakamori S, Sekimoto M, Matsuura N, Monden M. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin Cancer Res 2003, 9:1764-1772.
22. Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, Matsuzuka F, Matsuura N, Kakudo K, Kuma K, Miyauchi A. Expression of cdc25A and cdc25B proteins in thyroid neoplasms. Br J Cancer 2002, 86:1909-1913. 10.1038/sj.bjc.6600364, 2375432, 12085185.
23. Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003, 22:734-739. 10.1038/sj.onc.1206121, 12569365.
24. Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, Tahara E. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res 1997, 88:947-952.
25. Hernandez S, Bessa X, Bea S, Hernandez L, Nadal A, Mallofre C, Muntane J, Castells A, Fernandez PL, Cardesa A, Campo E. Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest 2001, 81:465-473.
26. Miyata H, Doki Y, Shiozaki H, Inoue M, Yano M, Fujiwara Y, Yamamoto H, Nishioka K, Kishi K, Monden M. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res 2000, 6:4859-4865.
27. Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, Giese T, Korc M, Buchler MW, Friess H. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 2004, 23:71-81. 10.1038/sj.onc.1206926, 14712212.
28. Dalal SN, Yaffe MB, DeCaprio JA. 14-3-3 family members act coordinately to regulate mitotic progression. Cell Cycle 2004, 3:672-677.
29. Mailand N, Podtelejnikov AV, Groth A, Mann M, Bartek J, Lukas J. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J 2002, 21:5911-5920. 10.1093/emboj/cdf567, 131064, 12411508.
30. Bugler B, Quaranta M, Aressy B, Brezak MC, Prevost G, Ducommun B. Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol Cancer Ther 2006, 5:1446-1451. 10.1158/1535-7163.MCT-06-0099, 16818502.
31. Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J. Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J Cell Biol 1999, 146:573-584. 10.1083/jcb.146.3.573, 2150562, 10444066.
32. Escalas N, Davezac N, De RJ, Baldin V, Mazars R, Ducommun B. Study of the cytolethal distending toxin-induced cell cycle arrest in HeLa cells: involvement of the CDC25 phosphatase. Exp Cell Res 2000, 257:206-212. 10.1006/excr.2000.4878, 10854069.
33. Bansal P, Lazo JS. Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res 2007, 67:3356-3363. 10.1158/0008-5472.CAN-06-3685, 17409445.
34. Nagata A, Igarashi M, Jinno S, Suto K, Okayama H. An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. New Biol 1991, 3:959-968.
35. Spitkovsky D, Jansen-Durr P, Karsenti E, Hoffman I. S-phase induction by adenovirus E1A requires activation of cdc25a tyrosine phosphatase. Oncogene 1996, 12:2549-2554.
36. Nakabayashi H, Hara M, Shimizu K. Prognostic significance of CDC25B expression in gliomas. J Clin Pathol 2006, 59:725-728. 10.1136/jcp.2005.029546, 1860415, 16803948.
37. Hu YC, Lam KY, Law S, Wong J, Srivastava G. Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin Cancer Res 2001, 7:2213-2221.
38. Bulavin DV, Higashimoto Y, Demidenko ZN, Meek S, Graves P, Phillips C, Zhao H, Moody SA, Appella E, Piwnica-Worms H, Fornace AJ. Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol 2003, 5:545-551. 10.1038/ncb994, 12766774.